Get the latest news, insights, and market updates on ZNTL (Zentalis Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference, Virtual. Fireside discussion, February 25, 2 Feb 18, 2026 - $ZNTL
Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon
Zentalis Pharmaceuticals (NASDAQ:ZNTL) executives outlined a strategy centered on advancing its WEE1 inhibitor azenosertib toward potential approval in platinum-resistant ovarian cancer (PROC), emphasizing a targeted approach in patients with high cyclin E1 protein expression. Speaking at a Guggenhe Feb 16, 2026 - $ZNTL
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11th in New York, NY at 3:30 p.m. ET. Access to a live web Feb 3, 2026 - $ZNTL
Mitsui Sumitomo Continues to Build WR Berkley Stake
W.R. Berkley and Navan have just seen some huge insider purchases. have seen some huge insider purchases, and there were some other notable insider purchases as well. Jan 13, 2026 - $ZNTL
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying
Zentalis Pharmaceuticals (ZNTL) has come into focus after progress in its azenosertib oncology program, including completed enrollment in the Phase 2 DENALI trial, FDA alignment on the Phase 3 ASPENOVA design, and a large insider share purchase. See our latest analysis for Zentalis Pharmaceuticals. The latest clinical milestones and insider buying have coincided with a sharp shift in sentiment, with a 7 day share price return of 172.99% and a 90 day share price return of 130.86%. However, the... Jan 11, 2026 - $ZNTL
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalInitiation of the ASPENOVA Phase 3, randomized, confirmatory trial planned in 1H 2026 SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-d Jan 6, 2026 - $ZNTL
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $280.7 million cash, cash equivalents and marketable securities supports runway into late 2027 SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class Nov 10, 2025 - $ZNTL
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference, Boston, MA. Fireside discussion, November 11, 2025, 3:30 p.m. ET. Stifel 2025 Nov 3, 2025 - $ZNTL
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple